Premium
Bordetella bronchiseptica experimental model development in pigs and efficacy evaluation of a single intramuscular injection of gamithromycin (Zactran® for Swine) against Bordetella bronchiseptica‐ associated respiratory disease in experimentally infected piglets
Author(s) -
Gupta Aradhana,
CortesDubly MarieLaure,
Buellet Prescillia,
RichardMazet Alexandra,
Merdy Olivier,
Targa Norba L.,
Dumont Pascal
Publication year - 2020
Publication title -
journal of veterinary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.527
H-Index - 60
eISSN - 1365-2885
pISSN - 0140-7783
DOI - 10.1111/jvp.12834
Subject(s) - bordetella bronchiseptica , saline , medicine , bovine respiratory disease , respiratory system , anesthesia , biology , immunology , bacteria , genetics
In the Bordetella bronchiseptica infection model development study, twenty‐eight piglets were inoculated with B. bronchiseptica strain of either canine (10 9 CFU/ml) or swine (10 8 and 10 9 CFU/ml) origin; swine origin strain at 10 9 CFU/ml was chosen for the efficacy assessment study due to higher incidence and severity of gross and histopathological lesions compared with other strains. To assess efficacy of gamithromycin against B. bronchiseptica , forty piglets were experimentally inoculated on Day 0 and clinical signs were scored as per severity. Animals were then treated either with gamithromycin or saline on Day 3. The Global Clinical Scores in gamithromycin‐treated group were consistently lower than the saline‐treated control group from Day 4 onwards and were 0 and 40 in the gamithromycin‐treated and saline‐treated control groups, respectively, on Day 6. Severity and frequency of gross and histopathological observations were significantly lower in gamithromycin‐treated animals compared with saline‐treated controls. The efficacy of Zactran® for Swine at the label dose for the treatment of B. bronchiseptica –associated respiratory disease was demonstrated based on the faster reduction in clinical signs as early as 1 day post‐gamithromycin treatment and based on the significant difference in the severity of macroscopic and microscopic lung lesions 10 days post‐gamithromycin treatment.